there should be a conference call soon, though I can' find the date. Can they afford to take another year to harvest data? DCaf is correct about credibility. That, and a seeming absence of urgency could be their undoing.
My point is to move Tusp in Flt3i failures quickly. You don't have a "luxury" to explore other opportunities with resources you have. I understand your expectations for good results from combo studies but there is a difference between what you want and what you can. My view is that all combo phase 3 trials don't belong here. Let some bigger and more experienced company do it. Any rise in SP caused by good data will be neutralized by dilutions here. Rice wasted too much time and money. Finish a registrational Ph2 study and sell the company.
News 
Market Data 
Discover 
AI
